解析伴抗磷脂综合征的系统性红斑狼疮之谜:全血转录组分析揭示干扰素特征减弱及静脉与动脉事件不同的分子谱
该研究分析299例系统性红斑狼疮(SLE)患者(108例抗磷脂抗体阳性,含67例SLE-APS;191例抗磷脂抗体阴性)及72例健康对照的全血RNA测序数据,发现SLE-APS患者I型和II型干扰素通路较健康对照上调,但与抗磷脂抗体阴性SLE相比干扰素特征减弱,静脉血栓与中性粒细胞/髓系及B细胞模块相关,动脉血栓与DNA损伤应答和代谢模块失调相关。
要点
- SLE-APS患者I型和II型干扰素通路较健康对照上调。
- SLE-APS较抗磷脂抗体阴性SLE的IFN-α和IFN-γ特征下调,补体、B细胞活化及中性粒细胞脱颗粒失调。
- SLE-APS中静脉血栓与中性粒细胞/髓系和B细胞模块正相关,动脉血栓与DNA损伤应答和代谢模块失调相关。
核心结论
- SLE中干扰素呈层级性上调且可能依赖干扰素,抗磷脂抗体阴性SLE患者的干扰素特征最高。
- 静脉血栓事件与中性粒细胞和B细胞相关,动脉事件与DNA损伤应答和代谢受损相关。
- 上述差异可能解释对抗凝治疗的不同需求,并为SLE-APS中潜在使用mTOR抑制剂(如西罗莫司)和直接fIIa抑制剂达比加群提供依据。
研究设计与样本
- 研究分析299例SLE患者(108例抗磷脂抗体阳性,含67例SLE-APS;191例抗磷脂抗体阴性)及72例匹配健康对照的全血RNA测序数据。
- 采用通路富集分析、无监督加权基因共表达网络分析和机器学习区分疾病内型。
主要发现
- SLE-APS患者与健康对照相比,I型和II型干扰素通路上调。
- 采用100基因随机森林模型区分SLE-APS与健康对照的交叉验证准确率为75.6%。
- SLE-APS与抗磷脂抗体阴性SLE比较发现227个差异表达基因,提示IFN-α和IFN-γ特征下调,伴补体级联、B细胞活化和中性粒细胞脱颗粒失调。
- SLE转录组无监督分析识别21个基因模块,SLE-APS与「中性粒细胞/髓系」模块上调强相关。
- SLE-APS中,静脉血栓与「中性粒细胞/髓系」和「B细胞」模块正相关;动脉血栓与「DNA损伤应答」和「代谢」模块失调相关。
临床怎么用
- 原文未据此给出推荐。
- 作者认为上述差异可能解释SLE-APS对抗凝治疗的不同需求,并为潜在使用mTOR抑制剂(如西罗莫司)和直接fIIa抑制剂达比加群提供依据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Systemic lupus erythematosus with antiphospholipid syndrome (SLE-APS) represents a challenging SLE endotype whose molecular basis remains unknown. METHODS: We analysed whole-blood RNA-sequencing data from 299 patients with SLE (108 SLE-antiphospholipid antibodies (aPL)-positive, including 67 SLE-APS; 191 SLE-aPL-negative) and 72 matched healthy controls (HC). Pathway enrichment analysis, unsupervised weighted gene coexpression network analysis and machine learning were applied to distinguish disease endotypes. RESULTS: Patients with SLE-APS demonstrated upregulated type I and II interferon (IFN) pathways compared with HC. Using a 100-gene random forests model, we achieved a cross-validated accuracy of 75.6% in distinguishing these two states. Additionally, the comparison between SLE-APS and SLE-aPL-negative revealed 227 differentially expressed genes, indicating downregulation of IFN-α and IFN-γ signatures, coupled with dysregulation of the complement cascade, B-cell activation and neutrophil degranulation. Unsupervised analysis of SLE transcriptome identified 21 gene modules, with SLE-APS strongly linked to upregulation of the 'neutrophilic/myeloid' module. Within SLE-APS, venous thromboses positively correlated with 'neutrophilic/myeloid' and 'B cell' modules, while arterial thromboses were associated with dysregulation of 'DNA damage response (DDR)' and 'metabolism' modules. Anticardiolipin and anti-β2GPI positivity-irrespective of APS status-were associated with the 'neutrophilic/myeloid' and 'protein-binding' module, respectively. CONCLUSIONS: There is a hierarchical upregulation and-likely-dependence on IFN in SLE with the highest IFN signature observed in SLE-aPL-negative patients. Venous thrombotic events are associated with neutrophils and B cells while arterial events with DDR and impaired metabolism. This may account for their differential requirements for anticoagulation and provide rationale for the potential use of mTOR inhibitors such as sirolimus and the direct fIIa inhibitor dabigatran in SLE-APS.
引用
- Nikolopoulos D, Loukogiannaki C, Sentis G, et al. Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events. Ann Rheum Dis. 2024. PMID: 38609158. doi:10.1136/ard-2024-225664
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。